[ad_1]
The delivery of the vaccine developed by Pfizer, in collaboration with Biontech, has been negotiated in the European Union, for 200 million doses, to which an additional batch of another 100 million doses can be added.
According to a statement from the manufacturer Pfizer, the batches of coronavirus vaccine that will reach the European Union are manufactured in the Biontech laboratories in Germany, respectively the Pfizer laboratories in Belgium.
The manufacturer has agreed with EU representatives that the first deliveries of the vaccine will begin later this year, in December 2020.
Given the unitary policy of the European Union, whose officials have announced that they will send doses of vaccine at the same time to all European countries, this means that the Pfizer vaccine could reach Romania in the first part of 2021.
Details of the contract will be negotiated in the coming days by Pfizer with the EU, the drugmaker said in a statement.
If the pharmaceutical manufacturer receives regulatory approval for vaccine candidate doses, the European Commission will assign the vaccine doses to the 27 EU member states.
“The anticipated agreement between Pfizer and BioNTech with the European Commission is an important step forward in our common goal of having millions of doses of the COVID-19 vaccine available to the vulnerable population before the end of the year. We would like to thank the European Commission your commitment and confidence in our development efforts “, said Albert Bourla, president of Pfizer.
“We have activated our supply chain at our facilities in Belgium and we are starting production so that our vaccine is available as soon as possible, if our clinical trials are successful and regulatory approval is granted.” specific.
BioNTech co-founder Ugur Sahin said he would honor the largest order for pharmaceuticals to date.
“As a company founded in the heart of Europe, we are pleased to have concluded advanced discussions with the European Commission for our largest initial order to date. Our goal is to develop a safe and effective vaccine to help stop this pandemic in Europe and across the world. Today’s decision is yet another illustration of how collaboration and solidarity can help address a global health crisis as an international community. “ Sahin said.
The coronavirus vaccine developed by pharmaceutical giant Pfizer and German biotechnology company BioNTech is more than 90% efficient, according to an interim analysis by an independent evaluation commission. In the Pfizer study, of the 44,000 people monitored, there were 94 cases of Covid-19 in people who had not been previously infected.
Fewer than 9 of these cases occurred among people who received two doses of the vaccine, a strong sign of its effectiveness.
The data is not yet public or evaluated by other researchers, and the company’s press release could not be presented to external experts due to the existence of an embargo on it.
